Treatment | TRa(%) | TTRb(95% CI) |
P
e
| TP470c(%) | TTPd(95% CI) |
P
|
|---|
E2-Dox | 0 | NAf (NA-NA) | 1 | 100 | 8 (5–12) | 0.671 |
E2 + Dox | 0 | NA (NA-NA) |  | 100 | 10 (6–13) |  |
ED-Dox | 100 | 25 (6–39) | 0.011 | 13 | NA (223-NA) | 0.098 |
ED + Dox | 64 | 108 (30-NA) | Â | 43 | NA (41-NA) | Â |
Tam-Dox | 71 | 24 (9-NA) | 0.002 | 71 | 86 (73-NA) | 0.022 |
Tam + Dox | 24 | NA (43-NA) |  | 94 | 54 (36–71) |  |
Ful-Dox | 100 | 17 (6–24) | <0.001 | 14 | NA (462-NA) | 0.107 |
Ful + Dox | 73 | 107 (38–198) |  | 47 | NA (101-NA) |  |
- aTR is the fraction of mice achieving tumor regression, defined by the tumor size halving since the randomization; bTTR is the median time to tumor regression with 95% confidence interval; cTP470 is the fraction of mice experiencing tumor progression within 470 days after treatment, defined by the tumor size doubling since the randomization; dTTP is the median time to tumor progression with 95% confidence interval; eP value is based on the generalized Wilcoxon test comparing the -/+Dox groups in each endocrine treatment arm; fNA = not-achieved. PTEN, phosphatase and tensin homolog; WT, wild-type; Dox, doxycycline; KD, knockdown; TTR, time to tumor regression; TTP, time to tumor progression; E2, β-estradiol; ED, estrogen deprivation; Tam, tamoxifen; Ful, fulvestrant.
